Study 111-212 is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to assess the safety and efficacy of vosoritide versus placebo in infants and young children with HCH.
The purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to less than 36 months over a 52-week period.
Study ID: 4828
NCT Number: NCT07126262
Principal Investigator: Daniel Hoernschemeyer, MD
Department: Orthopaedic Surgery
For questions about this study, please contact:
ClinicalTrialsInterest@health.missouri.edu(573) 882-7026